127 related articles for article (PubMed ID: 38926425)
41. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects.
Peng S; Tomson TT; Trimble C; He L; Hung CF; Wu TC
Gene Ther; 2006 Feb; 13(3):257-65. PubMed ID: 16177818
[TBL] [Abstract][Full Text] [Related]
42. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
43. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
44. Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7.
Duan F; Chen J; Yao H; Wang Y; Jia Y; Ling Z; Feng Y; Pan Z; Yin Y; Jiao X
Hum Vaccin Immunother; 2021 Jun; 17(6):1568-1577. PubMed ID: 33449866
[TBL] [Abstract][Full Text] [Related]
45. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
[TBL] [Abstract][Full Text] [Related]
46. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
[TBL] [Abstract][Full Text] [Related]
47. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
[TBL] [Abstract][Full Text] [Related]
48. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
49. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
50. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Alphs HH; Gambhira R; Karanam B; Roberts JN; Jagu S; Schiller JT; Zeng W; Jackson DC; Roden RB
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5850-5. PubMed ID: 18413606
[TBL] [Abstract][Full Text] [Related]
51. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
[TBL] [Abstract][Full Text] [Related]
52. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
54. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice.
Whitehead M; Ohlschläger P; Almajhdi FN; Alloza L; Marzábal P; Meyers AE; Hitzeroth II; Rybicki EP
BMC Cancer; 2014 May; 14():367. PubMed ID: 24885328
[TBL] [Abstract][Full Text] [Related]
56. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
57. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
58. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
59. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
60. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice.
McCarthy C; Youde SJ; Man S
Int J Cancer; 2006 May; 118(10):2514-21. PubMed ID: 16353149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]